Tivicay
Tivicay is the brand name for dolutegravir, an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase strand transfer inhibitors (INSTIs), which work by blocking the integration of HIV DNA into the host genome, thereby reducing viral replication. Dolutegravir is prescribed as part of combination antiretroviral therapy (cART) in adults and in certain pediatric populations.
Dolutegravir is approved for use in treatment-naive and certain treatment-experienced patients, typically as part of fixed‑dose
The usual adult dose is 50 mg once daily. If used with rifampin-containing regimens (for tuberculosis), the
Common adverse effects include trouble sleeping, headache, and fatigue. Some patients may experience weight changes or
Tivicay is marketed by ViiV Healthcare and is available in multiple countries under appropriate regulatory approvals.